Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.50 |
| ▸ | SLC40A1 | Q9NP59 | 5/20 | 0.47 |
| ▸ | GLO1 | Q04760 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | NMT1 | P30419 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3532837 | 0.79 | GLO1 (0.57) | ALDH1A1LMNAPIK3CAGLO1MEN1 | |
| SCHEMBL3535146 | 0.76 | SLC40A1 (0.61) | PIK3CASLC40A1GLO1MEN1KMT2A | |
| SCHEMBL3533105 | 0.76 | SLC40A1 (0.55) | SLC40A1GLO1KMT2ACYP2C19 | |
| SCHEMBL3534093 | 0.76 | ATM (0.62) | ALDH1A1SLC40A1MEN1KMT2ATDP1 | |
| SCHEMBL9930803 | 0.75 | CCR2 (0.67) | LMNAGLO1TDP1 | |
| SCHEMBL6981076 | 0.74 | ALDH1A1 (0.76) | ALDH1A1LMNASMN1; SMN2PIK3CASLC40A1 | |
| SCHEMBL3530032 | 0.73 | APP (0.42) | ALDH1A1SLC40A1 | |
| SCHEMBL3535998 | 0.72 | NFE2L2 (0.61) | ALDH1A1LMNASLC40A1GLO1 | |
| SCHEMBL3528452 | 0.72 | CYP2C9 (0.59) | ALDH1A1LMNASMN1; SMN2KMT2ACYP2C9 | |
| SCHEMBL3529882 | 0.72 | GLO1 (0.54) | ALDH1A1LMNASMN1; SMN2GLO1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728002-B2 | Use of pyrrolopyridine compounds for activating PPAR receptors and treatment of conditions involving such receptors | LABORATOIRES FOURNIER S.A. (FR) | 2010-06-01 | — | — | US | disclosed |
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | LABORATOIRES FOURNIER S.A. (FR) | 2009-09-24 | — | — | US | disclosed |
| EP-1919474-B1 | PYRROLOPYRIDINE DERIVATIVES AND USE OF SAME AS PPAR RECEPTOR MODULATORS | FOURNIER LAB SA (FR) | 2009-08-05 | — | — | EP | disclosed |
| US-7557122-B2 | Pyrrolopyridine compounds, method of making them and uses thereof | LABORATOIRES FOURNIER S.A. (FR) | 2009-07-07 | — | — | US | disclosed |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LABORATOIRES FOURNIER S.A. (FR) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | PPARD, PPARA, PPARG | ALDH1A1 1314/4885LMNA 2198/4885SMN1; SMN2 3212/4885 |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LIPG, PCSK9, PNLIP | ALDH1A1 1350/4885LMNA 2360/4885SMN1; SMN2 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.